Parkinson’s Disease Therapeutics Market Forecast (2017-2023) by Therapeutics, Drivers, Top 10 Companies
Market
Landscape:
The
recent report by Market Research Future (MRFR) asserts that the global Parkinson’s
Disease Therapeutics market 2020 is slated to acquire a substantial market
valuation at a moderate CAGR over the review period.
Drivers
and Restraints:
Global
Parkinson’s
Disease Therapeutics Market is anticipated to witness significant
growth, owing to the increasing cases of Parkinson’s disease, with the growth
in aging population levels. Furthermore, increasing environmental factors &
genetic heredity is augmenting the growth of Parkinson’s disease therapeutics
market. Therefore, it may drastically result in expanding the market
size during the forecast period. Pharmaceutical firms are creating
new and improved therapies for Parkinson's disease (PD), and lately, there have
been some significant product launches in Parkinson's disease
therapeutics and other assistive therapeutics. Additionally, most of the global
firms have a healthy drug pipeline for the treatment of Parkinson's disease,
and as per the estimations, the forecast period may observe the launch of a few
blockbuster drugs.
Competitive
Analysis:
·
GlaxoSmithKline Plc
·
Salix Pharmaceuticals
·
Impax Laboratories
·
Teva Pharmaceutical Industries Ltd
·
Apotex Inc
·
Novartis AG
·
Mylan N.V.
·
Orion Corporation
·
Par Pharmaceutical
·
Cipla Inc
·
Daiichi Sankyo
·
Wockhardt Limited
Segmental
Analysis:
·
The global Parkinson’s disease therapeutics
market is analyzed on the basis of type, treatment, and end-user.
·
The global Parkinson’s disease therapeutics
market, based on the treatment type, is bifurcated into medication and surgical
therapy. The medication segment is segmented further into COMT inhibitors, peripheral
decarboxylase inhibitors, MAO inhibitors, dopamine precursors, and others.
Surgery therapy is further bifurcated into deep brain stimulation (DBS) and
carbidopa/levodopa enteral suspension.
·
On the basis of end-user, the Parkinson’s
Disease Therapeutics market is categorized into hospitals & clinics,
academic & industrial research, and others.
Regional
Analysis:
The
geographical analysis of the Global Parkinson’s Disease Therapeutics Market has
been conducted in four major regions, namely the Asia Pacific, Europe, North
America, Latin America, and the Middle East and Africa.
Parkinson’s
disease therapeutics market is led by North America owing to the rising
healthcare spending that contributes to improving the market growth in this
region. The total number of Parkinson’s disease patients, combined with
the availability of reimbursements and high awareness, is boosting the growth
of the market. Additionally, the high cost of Parkinson's disease therapeutics
in the United States also leads to significant market size in terms of
revenue.
It
is projected that Europe stands second in the global Parkinson’s disease
therapeutics market. The increasing government initiatives to promote the
healthcare sector and augmented adoption of research and development projects
for chronic diseases in the healthcare domain fuel the market in this
region. Moreover, the entry of market players into strategic partnerships and
collaborations with the chemical industry drives the growth of the market in
Europe.
The
Asia Pacific is likely to observe growth in the Parkinson’s disease
therapeutics market during the review period due to the rising number of
healthcare organizations, growing prevalence of Parkinson’s disease. Moreover,
the growing incidence of the geriatric population in the region influence
market growth. India, China, and Japan are the key market players in this
region, and the Asia Pacific is valued to be the fastest-growing market for
Parkinson’s disease therapeutics.
Comments
Post a Comment